Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 14/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12476642 | 0.87 | ADORA3 (0.46) | ADORA3ADORA2ATP53 | |
| SCHEMBL2024237 | 0.87 | MAPT (0.44) | ADORA3ADORA2AKDM4EAPP | |
| SCHEMBL2018131 | 0.87 | ADORA3 (0.43) | ADORA3ADORA2AAPP | |
| SCHEMBL2016668 | 0.87 | ADORA3 (0.44) | ADORA3ADORA2ATP53KDM4EAPP | |
| SCHEMBL2025922 | 0.87 | ADORA3 (0.43) | ADORA3ADORA2A | |
| SCHEMBL12476646 | 0.86 | ADORA3 (0.55) | ADORA3ADORA2AKDM4E | |
| SCHEMBL2019823 | 0.85 | ADORA3 (0.48) | ADORA3ADORA2AFLT3 | |
| SCHEMBL12575080 | 0.84 | ADORA3 (0.56) | ADORA3ADORA2ALRRK2TP53KDM4E | |
| SCHEMBL12476121 | 0.84 | ADORA3 (0.48) | ADORA3ADORA2ATP53APP | |
| SCHEMBL2027771 | 0.84 | ADORA3 (0.41) | ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329705-B2 | Substituted triazolo-pyrazine compounds | ARQULE, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329705-B2 | Substituted triazolo-pyrazine compounds | ARQULE, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329705-B2 | Substituted triazolo-pyrazine compounds | ARQULE, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| WO-2011082267-A2 | SUBSTITUTED TRIAZOLO-PYRAZINE COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160215-A1 | Substituted Triazolo-Pyrazine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160215-A1 | Substituted Triazolo-Pyrazine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160215-A1 | Substituted Triazolo-Pyrazine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160215-A1 | Substituted Triazolo-Pyrazine Compounds | MKI67, TP53, THPO | ADORA3 1835/4885ADORA2A 985/4885LRRK2 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.